These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15161675)

  • 1. Imatinib for small cell lung cancer, aiming for a target in vivo.
    Johnson BE
    Clin Cancer Res; 2004 May; 10(10):3235-6. PubMed ID: 15161675
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
    Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.
    Altundag O; Altundag K; Boruban C; Silay YS; Turen S
    Cancer; 2005 Nov; 104(9):2033-4; author reply 2034. PubMed ID: 16161057
    [No Abstract]   [Full Text] [Related]  

  • 5. Is KIT an important therapeutic target in small cell lung cancer?
    Heinrich MC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5825-8. PubMed ID: 14676102
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.
    Gambacorti-Passerini C; Piazza R; Tornaghi L; Pilotti S; Pogliani E
    J Natl Cancer Inst; 2004 Nov; 96(22):1723-4. PubMed ID: 15547187
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate.
    Johnson FM; Yang P; Newman RA; Donato NJ
    J Exp Ther Oncol; 2004 Dec; 4(4):317-25. PubMed ID: 15844661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib: the narrow line between immune tolerance and activation.
    Mohty M; Blaise D; Olive D; Gaugler B
    Trends Mol Med; 2005 Sep; 11(9):397-402. PubMed ID: 16087402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
    Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects.
    Rocha A; Azevedo I; Soares R
    J Cell Biochem; 2008 Feb; 103(2):607-14. PubMed ID: 17614352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B; Tirnitz-Parker JE; Olynyk JK
    Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory.
    Jensen PB; Sehested M; Langer SW; Hansen HH
    Cancer Treat Rev; 1999 Dec; 25(6):377-86. PubMed ID: 10644503
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of new drugs in small cell lung cancer: phase II agents first?
    Aisner J
    Cancer Treat Rep; 1987 Dec; 71(12):1131-3. PubMed ID: 2825989
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.